Researchers developed a novel gene signature that has prognostic value in patients with multiple myeloma who are treated with immunomodulatory derivatives. READ MORE
Research in Review
Researchers developed a model to estimate the cost per month of survival in patients treated with daratumumab, carfilzomib, and pomalidomide plus dexamethasone.
Researchers compared how total direct costs changed for patients treated with carfilzomib in combination with lenalidomide and dexamethasone.
A phase 3 head-to-head trial comparing the effectiveness of Kyprolis (carfilzomib) in combination with dexamethasone has shown better outcomes in patients with multiple myeloma than the current standard of care, which utilizes the drugs Velcade (bortezomib) plus dexamethasone.